11/21
07:40 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
11/21
07:40 am
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
11/21
06:23 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
11/21
06:23 am
fdmt
Rating for FDMT
Medium
Report
Rating for FDMT
11/14
05:25 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $39.00 price target on the stock.
High
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $39.00 price target on the stock.
11/14
04:43 pm
fdmt
Rating for FDMT
High
Report
Rating for FDMT
11/14
01:34 pm
fdmt
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
11/14
11:52 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
11/14
11:52 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT